



PATENT
Docket No. 265.00390101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boldogh et al.) Group Art Unit: 1653
Serial No.: 10/691,330)
Confirmation No.: 1384) Examiner: Chih Min Kam
Filed: October 22, 2003)
For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND
ANALOGS THEREOF AS INHIBITORS OF APOPTOSIS AND OTHER
CELLULAR DAMAGE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Supplemental Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Since this Supplemental Information Disclosure Statement is submitted after the receipt of an Office Action in the above-identified patent application, please charge Deposit Account No. 13-495 the fee of \$180 under 37 C.F.R. §§1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

Supplemental Information Disclosure Statement

Page 2 of 2

Applicant: Boldogh et al.

Serial No.: 10/691,330


Filed: October 22, 2003

Title: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS
INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.10:

The undersigned hereby certifies that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Name: Sara E. Wigant
"Express Mail" mailing label number:
EV 201894274 US
Date of Deposit: March 20, 2006


Respectfully submitted

By

Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228
Customer Number 26813

March 20, 2006
Date


By: Nancy A. Johnson
Nancy A. Johnson
Reg. No. 47,266
Direct Dial (612)305-4723



OMB No. 0651-0011

Page 1 of 1

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 265.00390101	Serial No.: 10/691,330
	Applicant(s): Boldogh et al.	Confirmation No.: 1384
	Application Filing Date: 22 October 2003	Group: 1653
	Information Disclosure Statement mailed: March <u>20</u> , 2006	

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		6,939,847	09/06/05	Stanton et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		None						

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	Polish Society of Psychiatry Psychogeriatric and Alzheimer's Disease Section, "Treatment of Psychiatric Disorders in Aged Patients," <i>First International Symposium on Colostrinin</i> , ReGen Therapeutics Plc, 1 December 2000, Lodz Poland, Brochure.

EXAMINER	Date Considered
-----------------	------------------------

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.